A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

NCT04996030 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Prioritization

Conditions

Acute Promyelocytic Leukemia

Interventions

DRUG: SY-2101
DRUG: Arsenic Trioxide

Sponsor

Syros Pharmaceuticals